Sign In
Buy DMAC
$5.65
-0.120 (-2.08%)
At Close: Jun 03, 2026
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
04:30pm, Wednesday, 27'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
08:30am, Wednesday, 20'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
04:15pm, Tuesday, 12'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
03:11pm, Thursday, 07'th May 2026
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
04:30pm, Wednesday, 06'th May 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
08:25am, Thursday, 30'th Apr 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
01:05am, Saturday, 18'th Apr 2026
DiaMedica Therapeutics (NASDAQ: DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor Conf
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
10:52am, Tuesday, 31'st Mar 2026
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
04:45pm, Monday, 30'th Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restrict
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
04:56am, Monday, 30'th Mar 2026
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages
04:42am, Sunday, 29'th Mar 2026
Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings report
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
08:25am, Monday, 23'rd Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
02:05am, Monday, 09'th Mar 2026
DiaMedica Therapeutics (NASDAQ: DMAC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect DiaMedica Therapeutics to post ea
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33
04:02am, Saturday, 07'th Mar 2026
DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
07:35am, Thursday, 05'th Mar 2026
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a
